Bradford Porcia T, Freedman D Michal, Goldstein Alisa M, Tucker Margaret A
Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Boulevard, Rockville, MD 20852, USA.
Arch Dermatol. 2010 Mar;146(3):265-72. doi: 10.1001/archdermatol.2010.2.
To quantify the risk of subsequent primary cancers among patients with primary cutaneous malignant melanoma.
Population-based registry study.
We evaluated data from 9 cancer registries of the Surveillance, Epidemiology, and End Results program from 1973-2006.
We included 89 515 patients who survived at least 2 months after their initial melanoma diagnosis.
Of the patients with melanoma, 10 857 (12.1%) developed 1 or more subsequent primary cancers. The overall risk of a subsequent primary cancer increased by 28% (observed to expected [O:E] ratio = 1.28). One quarter of the cancers were subsequent primary melanomas (O:E = 8.61). Women with head and neck melanoma and patients younger than 30 had markedly increased risks (O:E = 13.22 and 13.40, respectively) of developing a subsequent melanoma. Second melanomas were more likely to be thin than were the first of multiple primary melanomas (thickness at diagnosis <1.00 mm, 77.9% vs 70.3%, respectively; P < .001). Melanoma survivors had increased risk of developing several cancers; the most common cancers with elevated risks were breast, prostate, and non-Hodgkin lymphoma (O:E = 1.10, 1.15, and 1.25, respectively).
Melanoma survivors have an approximately 9-fold increased risk of developing subsequent melanoma compared with the general population. The risk remains elevated more than 20 years after the initial melanoma diagnosis. This increased risk may be owing to behavioral factors, genetic susceptibility, or medical surveillance. Although the percentage of subsequent primary melanomas thicker than 1 mm is lower than for the first of multiple primary melanomas, it is still substantial. Melanoma survivors should remain under surveillance not only for recurrence but also for future primary melanomas and other cancers.
量化原发性皮肤恶性黑色素瘤患者发生后续原发性癌症的风险。
基于人群的登记研究。
我们评估了监测、流行病学和最终结果计划中9个癌症登记处1973 - 2006年的数据。
我们纳入了89515例在初次黑色素瘤诊断后至少存活2个月的患者。
在黑色素瘤患者中,10857例(12.1%)发生了1种或更多种后续原发性癌症。后续原发性癌症的总体风险增加了28%(观察到的与预期的[O:E]比率 = 1.28)。四分之一的癌症是后续原发性黑色素瘤(O:E = 8.61)。头颈部黑色素瘤女性患者和30岁以下患者发生后续黑色素瘤的风险显著增加(O:E分别为13.22和13.40)。与多个原发性黑色素瘤中的第一个相比,第二个黑色素瘤更可能较薄(诊断时厚度<1.00 mm,分别为77.9%和70.3%;P < 0.001)。黑色素瘤幸存者发生多种癌症的风险增加;风险升高的最常见癌症是乳腺癌、前列腺癌和非霍奇金淋巴瘤(O:E分别为1.10、1.15和1.25)。
与普通人群相比,黑色素瘤幸存者发生后续黑色素瘤的风险增加约9倍。在初次黑色素瘤诊断后20多年,该风险仍然升高。这种风险增加可能归因于行为因素、遗传易感性或医学监测。尽管后续原发性黑色素瘤厚度超过1 mm的百分比低于多个原发性黑色素瘤中的第一个,但仍然相当可观。黑色素瘤幸存者不仅应接受复发监测,还应接受未来原发性黑色素瘤和其他癌症的监测。